References
1. Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC; Cancer Research UK Drug Development Office Phase I clinical trial.. A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2013 Dec;72(6):1343-52. doi: 10.1007/s00280-013-2320-9. PubMed PMID: 24141375.
2. Tahara N, Zandbergen HR, de Haas HJ, Petrov A, Pandurangi R, Yamaki T, Zhou J, Imaizumi T, Slart RH, Dyszlewski M, Scarabelli T, Kini A, Reutelingsperger C, Narula N, Fuster V, Narula J. Noninvasive molecular imaging of cell death in myocardial infarction using 111In-GSAO. Sci Rep. 2014 Oct 29;4:6826. doi: 10.1038/srep06826. PubMed PMID: 25351258; PubMed Central PMCID: PMC4212241.
3. Cadd VA, Hogg PJ, Harris AL, Feller SM. Molecular profiling of signalling proteins for effects induced by the anti-cancer compound GSAO with 400 antibodies. BMC Cancer. 2006 Jun 9;6:155. PubMed PMID: 16764713; PubMed Central PMCID: PMC1550423.
4. Elliott MA, Ford SJ, Prasad E, Dick LJ, Farmer H, Hogg PJ, Halbert GW. Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial. Int J Pharm. 2012 Apr 15;426(1-2):67-75. doi: 10.1016/j.ijpharm.2012.01.024. PubMed PMID: 22286018.
